Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study.

Chavannes NH, Schermer TR, Wouters EF, Akkermans RP, Dekhuijzen RP, Muris JW, van Weel C, van Schayck OC.

Int J Chron Obstruct Pulmon Dis. 2009;4:431-6. Epub 2009 Nov 29.

2.

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA.

Thorax. 2003 Aug;58(8):654-8.

3.

Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.

Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C.

Respir Med. 2009 Apr;103(4):542-51. doi: 10.1016/j.rmed.2008.11.003. Epub 2009 Jan 9.

4.

Inhaled corticosteroids for stable chronic obstructive pulmonary disease.

Yang IA, Clarke MS, Sim EH, Fong KM.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002991. doi: 10.1002/14651858.CD002991.pub3. Review.

PMID:
22786484
5.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
6.

Beclometasone for chronic obstructive pulmonary disease.

De Coster DA, Jones M, Thakrar N.

Cochrane Database Syst Rev. 2013 Oct 9;(10):CD009769. doi: 10.1002/14651858.CD009769.pub2. Review.

PMID:
24105424
7.

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

Calverley PM, Spencer S, Willits L, Burge PS, Jones PW; IOSLDE Study Group.

Chest. 2003 Oct;124(4):1350-6.

PMID:
14555565
8.

Diagnostic value of oral prednisolone test for chronic obstructive pulmonary disorders.

Broekhuizen BD, Sachs AP, Moons KG, Cheragwandi SA, Damsté HE, Wijnands GJ, Verheij TJ, Hoes AW.

Ann Fam Med. 2011 Mar-Apr;9(2):104-9. doi: 10.1370/afm.1223.

9.

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.

Ställberg B, Selroos O, Vogelmeier C, Andersson E, Ekström T, Larsson K.

Respir Res. 2009 Feb 19;10:11. doi: 10.1186/1465-9921-10-11.

10.

Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study.

de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW.

Chest. 2007 Dec;132(6):1741-7. Epub 2007 Jul 23.

PMID:
17646228
11.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
12.

Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients.

Kruis AL, van Adrichem J, Erkelens MR, Scheepers H, In 't Veen H, Muris JW, Chavannes NH.

Int J Chron Obstruct Pulmon Dis. 2010 Nov 25;5:407-13. doi: 10.2147/COPD.S9654.

13.

Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P.

Am J Respir Crit Care Med. 2002 Mar 1;165(5):698-703.

PMID:
11874817
14.

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Nannini LJ, Lasserson TJ, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD006829. doi: 10.1002/14651858.CD006829.pub2. Review.

15.

Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.

Howcroft M, Walters EH, Wood-Baker R, Walters JA.

Cochrane Database Syst Rev. 2016 Dec 19;12:CD005074. doi: 10.1002/14651858.CD005074.pub4. Review.

PMID:
27990628
16.

Comparison of oral and depot intra-muscular steroids in assessing steroid-responsiveness in COPD.

Eiser N, Phillips C, Wooler P, Partridge M.

COPD. 2004 Apr;1(1):33-40.

PMID:
16997737
17.

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.

Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD001288. doi: 10.1002/14651858.CD001288.pub4. Review.

PMID:
25178099
18.

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. doi: 10.2147/COPD.S27320. Epub 2012 Feb 3.

19.

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.

Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum in: Lancet Respir Med. 2013 May;1(3):186.

PMID:
24429127
20.

Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.

Sobieraj DM, White CM, Coleman CI.

Clin Ther. 2008 Aug;30(8):1416-25. doi: 10.1016/j.clinthera.2008.08.004.

PMID:
18803985

Supplemental Content

Support Center